

immunex

Immunex Corporation
New Business Development
51 University Street
Seattle, WA 98101

Telephone: 206-587-0430
Facsimile: 206-233-0644
e-mail: klanieckij@immunex.com

FAX MESSAGE - PLEASE DELIVER IMMEDIATELY

Send to: Examiner Phillip Gamble
U.S. Patent and Trademark Office

FAX: 703-305-3014

From: James E. Klaniecki

Date: December 7, 2001

No. of pages including this page: 3

FAX RECEIVED
DEC 07 2001
GROUP 1600

Our Ref: 2836-E

Serial No. 09/699,923

PLEASE DELIVER THIS FAX IMMEDIATELY TO:

EXAMINER PHILLIP GAMBEL
ART UNIT 1644

**Document submitted: Response to Restriction Requirement and
Requirement for Election of Species**

Please confirm receipt of this transmission via return fax (206) 233-0644

If transmission problems occur contact Liz McCarthy at 206-587-0430 Ext. 4764.

CONFIDENTIALITY NOTICE: This communication (including any accompanying page(s)) is intended solely for the use of the individual or entity named above and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, you are hereby notified that any copying, distribution or other unauthorized use of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U.S. Postal Service. Thank you.

#8
VC
12/30/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
David H. Lynch, et al.

Docket No.: 2836-E

Serial No: 09/699,923

Group Art Unit: 1644

Filed: October 30, 2000

Examiner: P. Gambel

For: METHOD FOR PREPARING DENDRITIC CELLS

RESPONSE TO RESTRICTION REQUIREMENT
AND REQUIREMENT FOR ELECTION OF SPECIES

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In the Office Action mailed 27 November 2001 (Paper No. 7), the Office requested Applicants to elect a single disclosed species for prosecution on the merits from the following groups:

- A). GM-CSF
- B). IL-4
- C). TNF- α
- D). IL-3
- E). c-kit ligand
- F). fusions of GM-CSF and IL-3
- G). CD40L
- H). CD40-specific antibody

Applicants hereby elect, without traverse, Group A, the species drawn to GM-CSF. Currently, claims 12, 15 and 29 are considered generic.

CONCLUSION

An early and favorable action is respectfully requested. If the Examiner believes that any issues could be resolved, or if the prosecution of the application could be

Response to Restriction Requirement and
Requirement for Election of Species

2836-C

expedited, by a telephone conference, Applicants invite the Examiner to telephone the undersigned at telephone number (206) 389-4145.

Respectfully submitted,



James E. Klaniecki
Registration No. 38,207

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone: (206) 470-4847
Facsimile: (206) 233-0644

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

I hereby certify that this Response to Restriction Requirement and Requirement for Election of Species is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703) 305-3014; Attention: Examiner Phillip Gambel, Group Art Unit 1644 on the date indicated below.

Date: December 6, 2001

Signed: 
Elizabeth M. McCarthy